FDA Approved: ZEPZELCA — Supplemental Application (Jazz Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ZEPZELCA (lurbinectedin) from Jazz Pharmaceuticals. This action pertains to the NDA for the drug (NDA213702).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Zepzelca (lurbinectedin)

Snippet

SUPPL AP for ZEPZELCA (LURBINECTEDIN)